Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Related TEVA
Benzinga's Option Alert Recap From March 24
Teva's Stock Inches Higher Amid Cost-Cutting Plan
Marketplace Roundtable: Biotech Hanging In The Balance (Seeking Alpha)
Related NVS
Gilead Looking To Buy Incyte? It Makes Sense
How The Ultra-Wealthy Are Helping Advance Health And Life Sciences
FDA Decision For Dupixent As Novartis Drives Its CAR-T (Seeking Alpha)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA


Related Articles (TEVA + NVS)

View Comments and Join the Discussion!